logo
  

Micro Focus Suspends Final Dividend - Quick Facts

Micro Focus International plc. (MCRO.L) said that its board is no longer recommending a final dividend for the year ended 31 October 2019 and therefore it plans to withdraw resolution relating to the approval of a proposed final dividend of 58.33 cents per ordinary share at its forthcoming Annual General Meeting. The move is due to the current increased macro uncertainty, which has been impacted by the global spread of COVID-19.

The company said it will consider paying a second interim dividend in respect of the year ended 31 October 2019 once there is some visibility on the effects of the COVID-19 on the company's business.

The company's Annual General Meeting will be held on 25 March 2020.

In view of the ongoing COVID-19 pandemic, Micro Focus is asking shareholders to appoint the Chairman as their proxy -- either electronically or by post-- with their voting instructions rather than attend the AGM in person.

The deadline for voting is on 23 March 2020 for shareholders and on 18 March 2020 for ADR shareholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning. Science and technology firm Danaher Corp. (DHR) announced Thursday that it has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion. Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance... Biopharmaceutical company Kite Pharma, a part of Gilead Sciences, Inc. (GILD), and biotechnology company Shoreline Biosciences, Inc. announced Thursday a strategic partnership to develop novel cell therapies across a variety of cancer targets. The partnership follows Kite's investment in Shoreline's...
RELATED NEWS
Follow RTT